Country: United States
Language: English
Source: NLM (National Library of Medicine)
FAMOTIDINE (UNII: 5QZO15J2Z8) (FAMOTIDINE - UNII:5QZO15J2Z8)
Aurobindo Pharma Limited
FAMOTIDINE
FAMOTIDINE 20 mg
ORAL
PRESCRIPTION DRUG
Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: - active duodenal ulcer (DU). - active gastric ulcer (GU). - symptomatic nonerosive gastroesophageal reflux disease (GERD). - erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: - treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). - reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2 ) receptor antagonists. Risk Summary Available data with H2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse development effects were observed with oral administrat
Famotidine Tablets USP, 20 mg are yellow, rounded square shaped, biconvex, film-coated tablets debossed with ‘CC’ on one side and ‘60’ on the other side. Bottles of 30 NDC 65862-859-30 Bottles of 100 NDC 65862-859-01 Bottles of 500 NDC 65862-859-05 Bottles of 1,000 NDC 65862-859-99 10 x 10 Unit-dose Tablets NDC 65862-859-78 Famotidine Tablets USP, 40 mg are white, rounded square shaped, biconvex, film-coated tablets debossed with ‘CC’ on one side and ‘61’ on the other side. Bottles of 30 NDC 65862-860-30 Bottles of 100 NDC 65862-860-01 Bottles of 500 NDC 65862-860-05 Bottles of 1,000 NDC 65862-860-99 10 x 10 Unit-dose Tablets NDC 65862-860-78 Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a USP tight, light-resistant container.
Abbreviated New Drug Application
FAMOTIDINE - FAMOTIDINE TABLET, FILM COATED AUROBINDO PHARMA LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE FAMOTIDINE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR FAMOTIDINE TABLETS. FAMOTIDINE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1986 INDICATIONS AND USAGE Famotidine is a histamine-2 (H ) receptor antagonist indicated (1): In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer. symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence. DOSAGE AND ADMINISTRATION Indication Recommended Dosage (2.1) _Adult and Pediatric Patients 40 kg and greater_ Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily _Adults_ Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. (2.1, 2.2) Administration (2.3): Take once daily before bedtime or twice daily in the morning and before bedtime with or without food. DOSAGE FORMS AND STRENGTHS Tablets: 20 mg, 40 mg (3) CONTRAINDICATIONS History of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H receptor antagonists. (4) WARNINGS AND PRECAUTIONS Central Nervous System (CNS) Adverse Reactions: Elderly patients and patients with renal impairment at increased risk; reduce the dosage. (2.2, 5.1, 8.5, 8.6) GI Malignancy: Absence of GI symptoms does not preclude the presence of gastric malignancy; 2 2 Read the complete document